Nectar Lifesciences sells menthol business to Ceph for Rs 20 crore as part of restructuring, aiming to focus on innovation and debt repayment.

• The deal covers APIs and formulations via a slump sale part of a broader business restructuring.
• Shareholder approval on August 4; expected completion by September 2025.
• Proceeds to repay debt fund growth, and potentially reward shareholders.